Skip to main content
Midas Edge

Anteris Technologies Global Corp.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

AVR$5.89-0.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, Financial Statement Schedules

Exhibits, Financial Statement Schedules

The following documents are filed as part of this report:

Financial Statements

Information in response to this Item is included in Part II, Item 8 of this Form 10-K.

Financial Statement Schedules

All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes thereto.

Exhibits

The following is a list of exhibits filed or furnished as part of this Form 10-K.

Exhibit Index

Exhibit · Description · Incorporated by Reference · Filed
Number · Form · Date · Number · Herewith
2.1 †Scheme Implementation Deed, dated August 13, 2024, by and between Anteris Technologies Global Corp. and Anteris Technologies LtdS-111/22/20242.1
3.1Second Amended and Restated Certificate of Incorporation of Anteris Technologies Global Corp.8-K12/16/20243.1
3.2Amended and Restated Bylaws of Anteris Technologies Global Corp.8-K12/16/20243.2
4.1Reference is made to Exhibits 3.1 through 3.2X
4.2Description of Registrant’s Securities10-KX
4.3Form of Common Stock Warrant10-Q11/12/20254.2
4.4Form of Confirmation Letter (containing the terms of the CDI Warrants)10-Q11/12/20254.3
10.1 +Anteris Technologies Global Corp. Equity Incentive PlanS-111/22/202410.1
10.2 +Admedus Ltd Employee Long Term Incentive PlanS-812/16/202499.2
10.3 +Anteris Technologies Ltd Employee Incentive PlanS-812/16/202499.3
10.4 +Form of Indemnification Agreement for Directors and OfficersS-111/22/202410.2
10.5 #†^Development Agreement, dated April 18, 2023, by and between v2vmedtech, inc. and Anteris Technologies CorporationS-111/22/202410.3
10.11 #†^Supply and Quality Agreement, dated May 15, 2024, by and between Anteris Aus Operations Pty Ltd and Harvey Industries Group Pty LtdS-111/22/202410.9
10.12 †^Second Amended and Restated Supply and License Agreement, dated June 1, 2018, between 4C Medical Technologies, Inc. and Admedus CorporationS-111/22/202410.10
10.13 †^Amendment No. 1 to Second Amended and Restated Supply and License Agreement, dated March 5, 2024, between 4C Medical Technologies, Inc. and Anteris Technologies CorporationS-111/22/202410.11
10.14 #†^Supply and Quality Agreement, dated November 16, 2021 between Anteris Technologies Corporation and Aran Biomedical TeorantaS-111/22/202410.12
10.16 #†^First Amended and Restated Services Agreement, dated February 21, 2021, by and between NPX Medical, LLC and Anteris Technologies CorporationS-111/22/202410.14
10.17Amendment No. 1 to First Amended and Restated Services Agreement, dated March 24, 2024, by and between NPX Medical, LLC and Anteris Technologies CorporationS-111/22/202410.15
10.18 #†^Master Services Agreement, dated June 1, 2021, by and between Anteris Technologies Corporation and Switchback Medical LLCS-111/22/202410.16
10.19 †^First Amended and Restated Master Services Agreement, dated July 28, 2025, by and between Anteris Technologies Corporation and Switchback Medical LLC10-Q11/12/202510.1
10.24 †^Combined Bioinformatics Master Services Agreement, dated September 1, 2021, by and between Anteris Technologies Corporation and Cardiovascular Research FoundationS-111/22/202410.18
10.25 #†^Lease of Part 26 Harris Road, Malaga, dated February 1, 2009, by and between Giacomel Pty Ltd, Verigen Australia Pty Ltd and Genzyme CorporationS-111/22/202410.19(a)
10.26 #†Deed of Variation of Lease, dated June 23, 2014, among Giacomel Pty Ltd, Admedus Biomanufacturing Pty Ltd, Genzyme Corporation and Admedus LtdS-111/22/202410.19(b)
10.27 #Deed of Extension and Variation, dated February 19, 2019, by and between Giacomel Pty Ltd, Admedus Biomanufacturing Pty Ltd and Admedus LtdS-111/22/202410.19(c)
10.28Deed of Assignment of Lease, dated March 28, 2023 by and between Giacomel Pty Ltd, Admedus Biomanufacturing Pty Ltd, Admedus Regen Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(d)
10.29 #Deed of Variation of Lease, dated June 12, 2023, by and between Giacomel Pty Ltd, Anteris Aus Operations Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(e)
10.30 #Deed of Extension and Variation of Lease, dated February 13, 2024, among Giacomel Pty Ltd, Anteris Aus Operations Pty Ltd and Anteris Technologies LtdS-111/22/202410.19(f)
10.31 #†^+Professional Services Agreement, dated September 3, 2021, between Anteris Technologies Corporation and Christopher Meduri, M.D.S-111/22/202410.20(a)
10.32 #†+Amendment No. 1 to Professional Services Agreement, dated May 1, 2023, between Anteris Technologies Corporation and Christopher Meduri, M.D.S-111/22/202410.20(b)
10.33 +^Amended and Restated Employment Agreement, dated November 18, 2024, by and between Anteris Technologies Global Corp. and Wayne PatersonS-111/22/202410.24
10.34 +†^Contract of Employment, dated November 19, 2024, by and between Anteris Technologies Ltd and Matthew McDonnellS-111/22/202410.25
10.35 +^Amended and Restated Employment Agreement, dated November 19, 2024, by and between Anteris Technologies Global Corp. and David St DenisS-111/22/202410.26
10.36 #Anteris Technologies Global Corp. Non-Employee Director Compensation PolicyS-111/22/202410.27
Exhibit · Description · Incorporated by Reference · Filed
Number · Form · Date · Number · Herewith
10.37 #†Contribution and Stock Purchase Agreement, dated April 18, 2023, by and among Anteris Technologies Corporation, v2vmedtech, inc., Dr. Vinayak Bapat, Urmi Bapat, Shalaka Bapat, Susheel Kodali, Michael McDonald and Christopher MeduriS-1/A12/9/202410.28
10.38Stock Purchase Agreement, dated January 20, 2026, by and among Anteris Technologies Global Corp. and Covidien Group S.à r.l.8-K1/22/202610.1
10.39Registration Rights Agreement, dated January 22, 2026, by and among Anteris Technologies Global Corp. and Covidien Group S.à r.l.X
10.40Investor Rights Agreement, dated January 22, 2026, by and among Anteris Technologies Global Corp. and Covidien Group S.à r.l.X
10.41Master Services Agreement, dated January 12, 2026, by and between Anteris Technologies Corporation and Bright Research Partners, Inc.X
14.1Code of Business Conduct and Ethics10-K3/12/202514.1
19.1Insider Trading and Securities Dealing Policy10-K3/12/202519.1
21.1Subsidiaries of the RegistrantX
23.1(a)Consent of Independent Registered Public Accounting Firm for Anteris Technologies Global Corp.X
23.2Consent for Future Market Insights, Inc.X
24.1Power of Attorney (included in the signature page hereto)X
31.1Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
31.2Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002X
32.1*Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
97.1Compensation Clawback Policy10-K3/12/202597.1

This certification attached as Exhibit 32.1 that accompanies this Form 10-K, is deemed furnished and not filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.

Certain identified information has been excluded from this exhibit pursuant to Rule 601(b)(10) of Regulation S-K because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

†

Certain information in this exhibit has been redacted pursuant to Item 601(a)(6) of Regulation S-K.

^

Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. Anteris Technologies Global Corp. agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

Management contract or compensatory plan, contract or arrangement.

Item 16

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.